Physician profile
Scott Schultz
NPI 1952124141
$1,792.78
in general payments reported to CMS, 2019-2025
20 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $22.59 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $256.78 | 2025 | Caplyta |
| Abbvie INC. | $211.19 | 2025 | |
| Corium, LLC | $197.09 | 2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $163.78 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $162.85 | 2025 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $148.58 | 2025 | Fanapt |
| Lundbeck LLC | $143.77 | 2024-2025 | Rexulti |
| Cumberland Pharmaceuticals, INC. | $101.73 | 2025 | Caldolor |
| Otsuka America Pharmaceutical, INC. | $67.79 | 2025 | Rexulti, Abilify Maintena |
| Tris Pharma INC | $67.44 | 2025 | Dyanavel Xr, Onyda Xr |
| Alkermes, INC. | $45.26 | 2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $38.90 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $34.16 | 2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $29.78 | 2025 | |
| Vertical Pharmaceuticals, LLC | $28.27 | 2025 | Relexxii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.03 | 2025 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $20.95 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $14.55 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.